EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve



Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve



British Journal of Haematology 114(4): 937-943, September



In peripheral blood stem cell transplantation (PBSCT), the number of CD34+ cells transplanted has been shown to correlate well with both rapidity and durability of engraftment. However, it is clear that engraftment does not necessarily correlate with total CD34+ cell numbers in some patients. Consequently, there is increasing interest in evaluating the role of CD34+ subsets in haemopoietic recovery as a more accurate marker of harvest quality. We analysed the numbers of CD34+ cell subsets, namely Thy-1+, L-Selectin+ and CD38-, and correlated this with engraftment in 86 patients undergoing PBSCT. Adequate engraftment was defined as being a platelet count greater than 50 x 10(9)/l and a neutrophil count greater than 1.0 x 10(9)/l. CD34+L-Selectin+ provided the best prediction of engraftment rapidity, although the improvement over total CD34+ cell dose was minor. Only the dose of CD34+Thy-1+ cells transplanted correlated with durable engraftment. The probability of adequate 3-month engraftment increased with the dose of CD34+ cells transplanted, but 10% of patients receiving > 5 x 10(6)/kg still showed poor engraftment at 3 months. However, all patients receiving > 2.5 x 10(5)/kg CD34+Thy-1+ showed adequate engraftment at this time point. We also demonstrated that CD34+Thy-1+ progenitors were restricted to the bone marrow under normal conditions and, during stem cell mobilization, their kinetics generally paralleled total CD34+ numbers.

(PDF emailed within 0-6 h: $19.90)

Accession: 010167149

Download citation: RISBibTeXText

PMID: 11564089

DOI: 10.1046/j.1365-2141.2001.03027.x



Related references

Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2x10(6) CD34+ cells/kg. CytoTherapy 6(4): 356-362, 2005

CD34+ cell, CFU-GM and nucleated cell dose predict engraftment but not survival following autologous purged bone marrow transplantation , yet do not predict outcomes following CD6+ T cell depleted allogeneic BMT. Blood 94(10 SUPPL 1 PART 1): 147a, Nov 15, 1999

Predictive value for engraftment and survival of total nucleated cell dose (TNC) as compared to CD34+ cell dose after autologous and allogeneic bone marrow transplant (BMT) for hematologic malignancies. Journal of Clinical Oncology 23(16_suppl): 6706-6706, 2016

CD34+ cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation. Experimental Hematology (Charlottesville) 29(12): 1484-1493, December, 2001

Total CD34+ cell content and CD34+CD33- subset predict time to neutrophil and platelet engraftment and hospital discharge in patients following high-dose chemotherapy with primed peripheral blood progenitor cells. Blood 84(10 SUPPL 1): 88A, 1994

Correlation of CD34+ versus colony-forming cell in bone marrow and mobilized peripheral blood stem cell harvests. Blood 90(10 SUPPL 1 PART 2): 336B, Nov 15, 1997

CD34+ cell dose, rather than CFU-GM or CFU-GEMM, is the best predictor of engraftment after T-cell depleted unrelated allogeneic bone marrow transplantation. Blood 94(10 SUPPL 1 PART 1): 145a, Nov 15, 1999

Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34+, CD34+38-, and week-6 CAFC assays predict poor engraftment. Experimental Hematology (Charlottesville) 28(12): 1325-1333, December, 2000

Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment. Experimental Hematology 28(12): 1325-1333, 2001

A Low CD34+ cell dose results in higher mortality and lower survival after blood or marrow stem cell transplantation from HLA-identical siblings Should 2 X 106 CD34+ cells/kg be considered the threshold?. Blood 94(10 SUPPL 1 PART 2): 388b, Nov 15, 1999

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?. Bone Marrow Transplantation 26(5): 489-496, 2000

Circulating but not bone marrow CD34+ cell counts in steady-state hematopoiesis are predictive for progenitor cell mobilization into the peripheral blood. British Journal of Haematology 87(SUPPL 1): 96, 1994

CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. CytoTherapy 8(4): 399-407, 2006